血清 microRNA-22 和 microRNA-126 水平对非小细胞肺癌发生和转移的预测价值：一项病例对照研究。

Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: a case-control study.

出版信息

Neoplasma. 2017;64(3):453-459. doi: 10.4149/neo_2017_317.

DOI:10.4149/neo_2017_317

Abstract

Presented study aims to explore the predictive values of serum microRNA-22 (miR-22) and miR-126 levels for non-small cell lung cancer (NSCLC) development and metastasis.A total of 127 NSCLC patients who were admitted in the First People's Hospital of Yancheng City from May, 2013 to May, 2015 were selected as the case group, including 71 cases of adenocarcinoma and 56 cases of squamous cell carcinoma. There were 112 healthy individuals selected as the control group. The qRT-PCR was performed to testify the serum miR-22 and miR-126 levels. Logistic regression analysis was conducted to analyze independent factors influencing NSCLC metastasis and receiver operating characteristic (ROC) curve was drawn to analyze the sensitivity and specificity of serum miR-22 and miR-126 levels in predicting NSCLC developments and metastasis.The serum miR-22 level was significantly higher in the case group than that in the control group, while the serum miR-126 level was lower in the case group as compared with that in the control group. Compared with squamous cell carcinoma patients, serum miR-22 level significantly increased, while serum miR-126 level decreased in patients with adenocarcinoma. Patients at III + IV stage showed increased serum miR-22 level and relatively decreased serum miR-126 level as compared to patients at I + II stage. Serum miR-22 level elevated in patients with metastasis; in contrast serum miR-126 level reduced in comparison to those without metastasis. In patients with familial inheritance, serum miR-22 level increased but serum miR-126 level decreased as compared to those without familial inheritance. The specificity and sensitivity of serum miR-22 and miR-126 levels in predicting NSCLC development were 99.11%, 84.30%, 82.68% and 96.40%, respectively. The specificity and sensitivity of serum miR-22 and miR-126 levels in predicting NSCLC metastasis were 59.74%, 96.00%, 84.00% and 62.30%, respectively.Results indicated that serum miR-22 and miR-126 levels may be used as the predicative biomarkers for NSCLC development and metastasis.

摘要

本研究旨在探讨血清 microRNA-22（miR-22）和 miR-126 水平对非小细胞肺癌（NSCLC）发展和转移的预测价值。选择 2013 年 5 月至 2015 年 5 月在盐城市第一人民医院收治的 127 例 NSCLC 患者为病例组，其中腺癌 71 例，鳞癌 56 例。选择 112 例健康个体作为对照组。采用 qRT-PCR 检测血清 miR-22 和 miR-126 水平。采用 logistic 回归分析 NSCLC 转移的独立影响因素，绘制受试者工作特征（ROC）曲线分析血清 miR-22 和 miR-126 水平预测 NSCLC 发展和转移的灵敏度和特异性。病例组血清 miR-22 水平明显高于对照组，而病例组血清 miR-126 水平明显低于对照组。与鳞癌患者相比，腺癌患者血清 miR-22 水平明显升高，而血清 miR-126 水平明显降低。Ⅲ+Ⅳ期患者血清 miR-22 水平升高，血清 miR-126 水平相对降低，与Ⅰ+Ⅱ期患者相比。转移患者血清 miR-22 水平升高，而无转移患者血清 miR-126 水平降低。有家族遗传史的患者血清 miR-22 水平升高，而血清 miR-126 水平降低，与无家族遗传史的患者相比。血清 miR-22 和 miR-126 水平预测 NSCLC 发生的特异性和敏感性分别为 99.11%、84.30%、82.68%和 96.40%。血清 miR-22 和 miR-126 水平预测 NSCLC 转移的特异性和敏感性分别为 59.74%、96.00%、84.00%和 62.30%。结果表明，血清 miR-22 和 miR-126 水平可能作为 NSCLC 发展和转移的预测生物标志物。